Item 1.01 Entry into a Material Definitive Agreement.

On March 29, 2023, Cyteir Therapeutics, Inc. (the "Company"), entered into a Lease Amendment and Termination Agreement (the "Amendment") with respect to the Lease (the "Lease") with 99 Hayden LLC, which covers certain laboratory and office space at Ledgemont Technology Center at 99 Hayden Avenue, Lexington, Massachusetts (the "Premises"). The Amendment amends the terms of the Lease to terminate the Lease as of April 1, 2023, subject to completion of the requisite surrender requirements, with respect to approximately 14,636 rentable square feet consisting of office and lab space located on two floors of the Premises, and 140 rentable square feet of storage space located on the Premises. Under the terms of the Amendment, the Company will retain and consolidate into the remaining 5,531 rentable square feet of office space under the Lease at the Premises, which will serve as the Company's principal executive office, until October 31, 2023, at which time the Lease will terminate in its entirety. Prior to the expiration of the Lease, the Company intends to assess its real estate needs and plan appropriately.

The foregoing description is a summary of certain material terms of the Amendment and is qualified in its entirety by the text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 1.02 Termination of a Material Definitive Agreement The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 1.02 of this Current Report on Form 8-K by reference.

This Current Report on Form 8-K includes forward-looking statements including the Company's plans to assess its real estate needs. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties. Applicable risks and uncertainties include, among others, that the Company may not be able to enter into future lease agreements on favorable terms if at all, and other risks and uncertainties are identified under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in any subsequent filings with the Securities and Exchange Commission. The forward-looking statements contained in this Current Report on Form 8-K are based on management's current views and plans with respect to future events, and Cyteir does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits


Exhibit
  No.     Description

10.1        Lease Amendment and Termination Argeement, by and between 99 Hayden LLC
          and Cyteir Therapeutics, Inc., dated as of March 29, 2023
104       Cover Page Interactive Data File (embedded within the inline XBRL
          document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses